Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism
Status:
Terminated
Trial end date:
2021-08-08
Target enrollment:
Participant gender:
Summary
- There is a knowledge gap associated with the management of patients with COVID-19 lung
injury and a laboratory picture compatible with disseminated intravascular coagulation
(DIC). Clinical data to date support that COVID-19 is associated with a prothrombotic
state that is not simply explained by an influx of more critically ill individuals.
- These patients suffer from severe respiratory failure; hypoxemia and ventilator
dependence are the primary concerns; ARDS with respiratory failure is frequently the
cause of death. Macroscopic and probable microvascular thromboembolic events are a major
concern in this population.
- When DIC is associated with COVID-19, it predicts a very poor prognosis.
- This study will evaluate the clinical efficacy and safety of low-dose IV bolus
tenecteplase (TNK) together with anticoagulation compared with control patients on
therapeutic anticoagulation alone in hospitalized adults diagnosed with COVID-19 and
acute intermediate-risk PE.
- Prospective, multicenter, randomized two-arm trial enrolling consecutive patients who
meet enrollment criteria.
- The study will generate evidence that low-dose TNK together with anticoagulation is
beneficial in these patients